Celcuity (CELC) Income from Non-Controlling Interests (2020 - 2021)

Celcuity (CELC) posted Income from Non-Controlling Interests of $21.0 for Q2 2021, down 12.5% on a QoQ basis from $24.0 in Q1 2021, and down 32.26% year-over-year from $31.0 in Q2 2020.

Celcuity (CELC) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends

Celcuity's Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at $21.0 for Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Celcuity 4.13 Bn 4.13 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 21.00
Mar 31, 2021 24.00
Sep 30, 2020 28.00
Jun 30, 2020 31.00